Rafał Stec

1.4k total citations
61 papers, 926 citations indexed

About

Rafał Stec is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Rafał Stec has authored 61 papers receiving a total of 926 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Rafał Stec's work include Renal cell carcinoma treatment (16 papers), Colorectal Cancer Treatments and Studies (11 papers) and Renal and related cancers (10 papers). Rafał Stec is often cited by papers focused on Renal cell carcinoma treatment (16 papers), Colorectal Cancer Treatments and Studies (11 papers) and Renal and related cancers (10 papers). Rafał Stec collaborates with scholars based in Poland, United States and Spain. Rafał Stec's co-authors include Cezary Szczylik, Lubomir Bodnar, Bartłomiej Grala, Arkadiusz Lubas, Wojciech Kozłowski, Stanisław Niemczyk, Michał Mączewski, Agnieszka Synowiec, Renata Duchnowska and Leszek Kraj and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Rafał Stec

57 papers receiving 920 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rafał Stec Poland 18 445 377 303 211 110 61 926
Berna C. Özdemir Switzerland 14 436 1.0× 496 1.3× 249 0.8× 248 1.2× 151 1.4× 47 1.2k
Jens Voortman Netherlands 19 358 0.8× 427 1.1× 157 0.5× 151 0.7× 97 0.9× 41 890
David Ransom Australia 18 524 1.2× 583 1.5× 185 0.6× 220 1.0× 173 1.6× 36 1.3k
Shreyas Joshi United States 16 376 0.8× 408 1.1× 552 1.8× 188 0.9× 259 2.4× 91 1.2k
Serena Wong United States 18 272 0.6× 168 0.4× 127 0.4× 110 0.5× 79 0.7× 47 786
Jacob Korach Israel 24 567 1.3× 311 0.8× 144 0.5× 109 0.5× 222 2.0× 107 1.6k
Stephanie Daignault‐Newton United States 18 460 1.0× 359 1.0× 439 1.4× 177 0.8× 172 1.6× 90 1.2k
F. Raja United Kingdom 6 497 1.1× 290 0.8× 112 0.4× 160 0.8× 230 2.1× 12 1.2k
Elizabeth R. Kessler United States 17 391 0.9× 462 1.2× 571 1.9× 219 1.0× 248 2.3× 87 1.2k
Yaqi Li China 19 606 1.4× 191 0.5× 180 0.6× 191 0.9× 142 1.3× 55 930

Countries citing papers authored by Rafał Stec

Since Specialization
Citations

This map shows the geographic impact of Rafał Stec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafał Stec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafał Stec more than expected).

Fields of papers citing papers by Rafał Stec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafał Stec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafał Stec. The network helps show where Rafał Stec may publish in the future.

Co-authorship network of co-authors of Rafał Stec

This figure shows the co-authorship network connecting the top 25 collaborators of Rafał Stec. A scholar is included among the top collaborators of Rafał Stec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafał Stec. Rafał Stec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brodaczewska, Klaudia, Roksana Iwanicka‐Nowicka, Marta Koblowska, et al.. (2025). Hypoxia alters the response of ovarian cancer cells to the mitomycin C drug. Frontiers in Cell and Developmental Biology. 13. 1575134–1575134. 1 indexed citations
3.
Chiang, Anne C., Noemı́ Reguart, Philipp J. Jost, et al.. (2024). 155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1. Immuno-Oncology Technology. 24. 100784–100784. 1 indexed citations
4.
Melero, Ignacio, Judy S. Wang, Martin Gutierrez, et al.. (2024). Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.. Journal of Clinical Oncology. 42(16_suppl). 2588–2588. 1 indexed citations
5.
Kraj, Leszek, et al.. (2024). Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma. Cancers. 16(23). 3945–3945. 1 indexed citations
6.
Saracyn, Marek, et al.. (2024). Theranostics in Renal Cell Carcinoma—A Step Towards New Opportunities or a Dead End—A Systematic Review. Pharmaceuticals. 17(12). 1721–1721. 1 indexed citations
7.
Charkiewicz, Radosław, Anetta Sulewska, Robert Mróz, et al.. (2023). Serum Insights: Leveraging the Power of miRNA Profiling as an Early Diagnostic Tool for Non-Small Cell Lung Cancer. Cancers. 15(20). 4910–4910. 6 indexed citations
8.
Górnicka, Barbara, et al.. (2023). Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. Cancer Immunology Immunotherapy. 72(7). 1971–1989. 17 indexed citations
9.
Charkiewicz, Radosław, Anetta Sulewska, Attila Gyenesei, et al.. (2023). miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping. International Journal of Molecular Sciences. 24(17). 13318–13318. 8 indexed citations
10.
Lubas, Arkadiusz, et al.. (2020). Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology. 146(8). 2099–2108. 6 indexed citations
11.
12.
13.
Stec, Rafał, et al.. (2016). Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?. Urologic Oncology Seminars and Original Investigations. 34(5). 215–220. 16 indexed citations
14.
15.
Stec, Rafał, Lubomir Bodnar, Radosław Charkiewicz, et al.. (2012). K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. Cancer Biology & Therapy. 13(13). 1235–1243. 11 indexed citations
16.
Bodnar, Lubomir, et al.. (2011). The role of Tau protein in resistance to paclitaxel. Cancer Chemotherapy and Pharmacology. 68(3). 553–557. 64 indexed citations
17.
Stec, Rafał, et al.. (2010). Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review). Oncology Letters. 2(1). 3–11. 7 indexed citations
18.
Bodnar, Lubomir, et al.. (2010). Cystatin C as a Parameter of Glomerular Filtration Rate in Patients with Ovarian Cancer. Kidney & Blood Pressure Research. 33(5). 360–367. 26 indexed citations
19.
Stec, Rafał, Lubomir Bodnar, & Cezary Szczylik. (2009). Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. Journal of Cancer Research and Clinical Oncology. 136(2). 283–292. 3 indexed citations
20.
Wcisło, Gabriel, et al.. (2006). Epidemiology of colorectal cancer. Contemporary Oncology/Współczesna Onkologia. 10(3). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Berna C. Özdemir Breakdown of academic impact, for papers by Jens Voortman Breakdown of academic impact, for papers by David Ransom Breakdown of academic impact, for papers by Shreyas Joshi Breakdown of academic impact, for papers by Serena Wong Breakdown of academic impact, for papers by Jacob Korach Breakdown of academic impact, for papers by Stephanie Daignault‐Newton Breakdown of academic impact, for papers by F. Raja Breakdown of academic impact, for papers by Elizabeth R. Kessler Breakdown of academic impact, for papers by Yaqi Li
Rankless by CCL
2026